Biodegradable Intraocular Implants Sustained Prostamide Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular hypertension, such as glaucoma, face limitations due to side effects from topical prostaglandin use and the need for frequent administration, which can be cosmetically undesirable and inconvenient for patients.
Innovation Solution
Development of intraocular implants comprising a prostamide component, like bimatoprost, combined with a biodegradable polymer matrix for sustained release of therapeutic agents, reducing intraocular pressure over extended periods with minimal side effects and eliminating the need for repeated administrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical prostaglandin administration is used to treat ocular hypertension, then intraocular pressure is reduced, but side effects occur and frequent administration is required
Solution Approach 1:
The patent uses a biodegradable polymer implant as an intermediary device that delivers prostaglandin analogs directly to the ocular tissue. This localized delivery system eliminates the need for topical administration and reduces systemic side effects while maintaining effective intraocular pressure control through sustained drug release over time
Solution Approach 2:
The patent employs pre-formed biodegradable implants that are surgically implanted to provide prolonged drug delivery. The implant is prepared in advance with controlled drug loading, eliminating the need for repeated patient administrations and providing continuous therapeutic effect through the degradation and release mechanism of the polymer matrix
2Reliability
If topical prostaglandin administration is used to treat ocular hypertension, then intraocular pressure is reduced, but frequent administration is required which is inconvenient
Solution Approach 1:
The patent implements continuous drug delivery through a biodegradable implant that releases prostaglandin analogs over an extended period (weeks to months). The sustained release mechanism maintains continuous therapeutic action on intraocular pressure without requiring repeated patient visits or administrations, thereby eliminating time loss associated with frequent dosing
3Loss of time
If intraocular implants with extended release are used, then administration frequency is reduced, but device complexity increases
Solution Approach 1:
The patent utilizes changes in the physical and chemical parameters of biodegradable polymers (such as degradation rate, molecular weight, and composition ratios) to control drug release kinetics. By adjusting these parameters, the implant achieves extended release functionality without requiring complex mechanical structures, thereby reducing device complexity while maintaining prolonged therapeutic effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The implants provide a consistent therapeutic effect for several weeks to months, effectively managing ocular hypertension with reduced side effects and improved patient convenience by maintaining a stable intraocular pressure level.
Implementation Method 1
sustain release of an amount of the prostamide component from the implant
Implementation Method 2
biodegradable polymer matrix
Data Source
AI summary
Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.